These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 37414756)

  • 1. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
    Shyam Sunder S; Sharma UC; Pokharel S
    Signal Transduct Target Ther; 2023 Jul; 8(1):262. PubMed ID: 37414756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
    Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
    ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
    Sun K; Wang X; Zhang H; Lin G; Jiang R
    Cancer Control; 2024; 31():10732748241278039. PubMed ID: 39159918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
    Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
    Lenihan DJ; Kowey PR
    Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
    Liu C; Amin R; Shatila M; Short N; Altan M; Shah A; Alhalabi O; Okhuysen P; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3965-3976. PubMed ID: 36030431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
    Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
    World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.
    Wang Z; Wang H; Bu C; Meng B; Mu Y; Gao S; Chen W; Tao X
    Eur J Clin Pharmacol; 2024 Jun; 80(6):827-838. PubMed ID: 38483545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.
    Qie W; Zhao Q; Yang L; Zou B; Duan Y; Yao Y; Wang L
    Cancer Med; 2023 Jul; 12(13):13873-13884. PubMed ID: 37017467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
    Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
    Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
    Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
    Josephs DH; Fisher DS; Spicer J; Flanagan RJ
    Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
    Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
    Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
    J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
    Johnson M; Garassino MC; Mok T; Mitsudomi T
    Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
    Brown SA; Nhola L; Herrmann J
    Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
    Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC
    Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Clin Lung Cancer; 2024 Sep; 25(6):e243-e251. PubMed ID: 38909011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.